“Europe’s Biotech Standout Faces Crucial Year After 1,300% Rally”
December 12, 2025
“French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for even more gains.
The optimism began in July when Abivax announced positive data for its experimental medicine to treat a chronic inflammatory bowel disease. That’s powered an ascent of more than 1,300% that makes the stock comfortably the best performer in Europe’s benchmark Stoxx 600 Index this year…”
https://finance.yahoo.com/news/europe-biotech-standout-faces-crucial-050000231.html